Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
BioLife Solutions Chief Quality and Operations officer Karen A. Foster reported open-market sales of a total of 97,423 shares of common stock in two transactions, at weighted average prices of $20.15 and $20.00 per share across multiple trades. After these sales, she directly owns 113,242 shares.
BioLife Solutions, Inc. (BLFS) filed a Form 144 reporting a transaction involving 500 common shares on 03/09/2026 tied to the exercise of stock options and settled for cash. The filing also lists recent 10b5-1 sales: 96,923 shares on 03/05/2026 for $1,953,163.22, 418 shares on 03/03/2026 for $8,669.32, and 335 shares on 01/06/2026 for $8,572.65.
BioLife Solutions Inc. reported that Chief Technology Officer Sean Werner executed an open-market sale of 111 shares of common stock on March 3, 2026 at $20.74 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan.
According to the filing, the trading plan, effective February 24, 2022, was established to satisfy tax withholding obligations arising from the vesting of restricted stock. After this sale, Werner directly holds 49,932 shares of BioLife Solutions common stock.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations, sold 418 shares of common stock in an open-market transaction at $20.74 per share. After this sale, she directly owned 210,665 shares. The sale was executed under a pre-established Rule 10b5-1(c) trading plan adopted to cover tax withholding tied to the vesting of restricted stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, sold 529 shares of common stock at $20.74 per share in an open‑market transaction. The sale was made under a Rule 10b5-1(c) trading plan adopted effective 02-24-2022 to cover tax withholding from vested restricted stock. After this sale, he directly held 392,937 common shares.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported an open-market sale of 588 shares of common stock at $20.74 per share. The transaction occurred on March 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan.
The footnote explains the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock. After this sale, Wichterman continues to hold 220,649 shares of BioLife Solutions common stock directly.
BioLife Solutions Inc. executive files small preplanned stock sale. Chief Human Resources Officer Sarah Aebersold sold 219 shares of common stock on March 3, 2026 in an open-market transaction at $20.74 per share. The sale was made under a Rule 10b5-1(c) trading plan adopted effective February 24, 2022 to satisfy tax withholding obligations from vested restricted stock. After this transaction, she directly holds 93,360 shares of BioLife Solutions common stock.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported an open-market sale of 353 shares of common stock at $20.74 per share on March 3, 2026. After this transaction, he directly held 165,940 shares of BioLife Solutions common stock.
According to the footnote, this sale was executed under a pre-established Rule 10b5-1(c) trading plan, adopted effective February 24, 2022. The plan was designed to satisfy tax withholding obligations related to the vesting of restricted stock, indicating the sale was part of a planned, tax-driven process rather than a discretionary trade.
KAREN FOSTER submitted a Form 144 notice for the proposed sale of 96,923 common shares of BLFS, to be effected on 03/05/2026 following the exercise of stock options and for cash. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker. The record also shows a prior sale by Ms. Foster of 335 common shares on 01/06/2026 for $8,572.65.
BioLife Solutions furnished an investor presentation outlining its position as a focused provider of biopreservation media and cell processing tools for cell-based therapies. For 2025, the company reports pro forma revenue of about $96 million, representing 29% organic growth after divesting storage, services and freezer businesses.
Adjusted EBITDA margin reached 26% in 2025, with adjusted EBITDA of roughly $25 million and gross margin around 65%, highlighting a shift to a higher-margin, consumables‑driven model. The materials state that BioLife products are specified in more than 70% of U.S. cell‑based therapy clinical trials and used in roughly 90% of commercially relevant FDA‑approved cell‑based therapies.
The presentation cites a cell‑based therapy market expected to grow over 20% annually through 2030 and a current addressable market of about $4 billion for BioLife’s offerings. Management is guiding to 17–20% revenue growth in 2026, with positive GAAP net income for the full year and continued adjusted EBITDA margin expansion.